Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.50 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.50 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12412836 | 0.90 | GRM5 (0.61) | GRM5MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL12412788 | 0.90 | GRM5 (0.71) | GRM5MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL12412029 | 0.89 | GRM5 (0.60) | GRM5MEN1KMT2ACSF1RBRAF | |
| SCHEMBL12412793 | 0.88 | GRM5 (0.72) | GRM5KMT2ACSF1R | |
| SCHEMBL12830497 | 0.88 | GRM5 (0.59) | GRM5 | |
| SCHEMBL12412802 | 0.86 | GRM5 (0.66) | GRM5 | |
| SCHEMBL12412795 | 0.86 | GRM5 (0.73) | GRM5BRAF | |
| SCHEMBL12411993 | 0.86 | GRM5 (0.59) | GRM5 | |
| SCHEMBL6927318 | 0.84 | GRM5 (1.00) | GRM5MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL12412776 | 0.84 | GRM5 (0.83) | GRM5MEN1KMT2AKCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501757-B2 | Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501757-B2 | Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-07 | — | — | US | disclosed |
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-07 | — | — | US | disclosed |
| WO-2011035214-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | GRM5 1/4885MEN1 4564/4885KMT2A 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.